MedTrace Logo

Single Ascending Dose Study of PBI-4547 in Healthy Subjects

NCT04068259 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-12-08

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of PBI-4547 in healthy adult participants.

Conditions

  • Healthy Subjects

Interventions

DRUG

PBI-4547

PBI-4547 tablet

OTHER

Placebo

Placebo tablet

Sponsors & Collaborators

  • Syneos Health

    collaborator OTHER

  • Liminal BioSciences Ltd.

    lead INDUSTRY

Principal Investigators

  • John Moran, MD · Prometic Pharma SMT Ltd.

  • Richard Larouche, MD · Syneos Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-05
Primary Completion
2019-10-08
Completion
2019-10-08

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04068259 on ClinicalTrials.gov